Dysmenorrhea

Health-E Commerce® shares 5 ways to use FSA or HSA funds to support women's health

Retrieved on: 
星期一, 四月 29, 2024
Inflammation, Stroke, Risk, Woman, Pregnancy, Health, Diabetes, Women's health, Fertility, Dysmenorrhea, Thyroid disease, Obesity, FSA, Mental health, Commerce, HSA, Oura, Sleep, Breast cancer, Birth control

DALLAS, April 29, 2024 /PRNewswire-PRWeb/ -- The hormonal changes that women experience throughout their lives put them at increased risk for serious or chronic health conditions like diabetes, stroke, obesity, and even breast cancer. Fortunately, managing everyday health can go a long way toward preventing the onset of these conditions. Now, as Women's Health Month kicks off, Health-E Commerce®, parent brand to FSA Store® and HSA Store®, is educating women who are enrolled in a flexible spending account (FSA) or health savings account (HSA) about how they can protect their health and manage the effects of hormonal changes – while also saving money by using their tax-free healthcare funds.

Key Points: 
  • There are numerous products and services available to support women on their health journeys.
  • FSA Store and HSA Store are proud to offer a wide variety of women's health products and a convenient, guaranteed-eligible shopping experience.
  • FSA Store and HSA Store are proud to offer a wide variety of women's health products and a convenient, guaranteed-eligible shopping experience."
  • To learn more about using tax-free funds to support women's health, visit the searchable eligibility lists at FSA Store or HSA Store .

Nika Pharmaceuticals, Inc. (NKPH) Purchased the Technologies for Three Drugs in Tablet Form and One Dietary Supplement

Retrieved on: 
星期一, 四月 15, 2024
Sale, Brain, Pain, Myalgia, Stroke, Woman, Tissue, Dietary supplement, Infertility, Infection, Testosterone, DSM-IV codes, Pelvic floor dysfunction, Male, Climacteric, Insomnia, System, Dementia, Dysmenorrhea, Erectile dysfunction, Lipid, Anxiety, Toothache, Oxygen, Headache, Acquisition, Memory, Libido, Tribulus terrestris, Tracheobronchitis, Fever, Metamizole

HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.

Key Points: 
  • HENDERSON, Nev., April 15, 2024 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCMKTS: NKPH) announces the purchase of four technologies for production of three generic drugs in tablet form and one dietary supplement.
  • The acquisition includes full dossiers for each product, which will allow NKPH to quickly register them for sale once the company has finalized the branding of each.
  • The technologies, which were purchased through NKPH’s subsidiary, Nika Europe Ltd., have a proven market track record, as each of them satisfy an important health need of the population.
  • MENTHYL VALERATE 60mg is an over-the-counter drug with a positive effect on the central nervous and cardiovascular systems.

Goodtime Family Care Saves 50% of Time Spent on Clinical Documentation with Sunoh.ai and eClinicalWorks EHR

Retrieved on: 
星期四, 四月 11, 2024
Other Health, Software, Managed Care, General Health, Data Management, Apps, Applications, Technology, Health Technology, Biotechnology, Practice Management, Other Technology, Health, Multimedia, Dysmenorrhea, EHR, HPI, Patient, Family, IOS, Android

eClinicalWorks® , the largest ambulatory cloud EHR and first AI-driven EHR, today announced that Goodtime Family Care has successfully implemented the medical AI scribe, Sunoh.ai , saving 50% of time spent on clinical documentation and other administrative tasks.

Key Points: 
  • eClinicalWorks® , the largest ambulatory cloud EHR and first AI-driven EHR, today announced that Goodtime Family Care has successfully implemented the medical AI scribe, Sunoh.ai , saving 50% of time spent on clinical documentation and other administrative tasks.
  • As a result of the eClinicalWorks integration with Sunoh.ai , the medical AI scribe is easily available to eClinicalWorks customers, including Goodtime Family Care.
  • Five years ago, the practice expanded its services, offering the Baltimore community comprehensive family care to foster healthy and happy families.
  • It's truly a time-saver during both patient visits and the post-visit process,” said Dr. Joseph Osuagwu, medical director at Goodtime Family Care.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Estetrol, INN, Pearl, Risk, Progesterone, Woman, IIA, ATC, Bleeding, International, Headache, Ageing, Language, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Liver, Medical Subject Headings, Marketing, Artery, Pregnancy, Coronary thrombosis, Estetrol, INN, Risk, Pearl, Progesterone, Woman, IIA, ATC, Health system, Bleeding, International, Headache, Ageing, Language, VTE, Mouth, Tablet, Dysmenorrhea, Acne, Birth control, European Medicines Agency, Blister, Menstrual cycle, Pearl Index, Select, Birth, Patient, Vein, Safety, Cancer, Checklist, Anatomy, Vaginal bleeding, Internal bleeding, Ovulation

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Retrieved on: 
星期三, 十二月 20, 2023
Food, Risk, Woman, Bloating, Diclofenac, FDA, Plasma, Dysmenorrhea, Nausea, Doctor of Philosophy, SAN, Pharmacokinetics, NSAID, Nonsteroidal anti-inflammatory drug, Menstruation, Observation, Safety, Vagina, Vomiting, Birth control

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.

Key Points: 
  • SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • The DARE-PDM1 Phase 1 study, DARE-PDM1-001, was a multi-center, randomized, placebo-controlled, double-blind, 3-arm parallel group study among approximately 42 healthy, premenopausal women with symptomatic primary dysmenorrhea.
  • The vaginal fluid PK results exhibited dose proportionality for the 1% and 3% diclofenac strengths of the DARE-PDM1 study treatment.
  • Pending the plasma PK data, the topline results of this Phase 1 study support continued clinical development of DARE-PDM1 for primary dysmenorrhea.

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Retrieved on: 
星期日, 十二月 10, 2023
Momentum, Agios Pharmaceuticals, Erythropoiesis, Sickle cell disease, Agios, Exposition, Hemoglobinopathy, Arm, BID, Trial of the century, University of Texas System, Sickle cell trait, Pain, Female, Headache, Disease, Fatigue, Dysmenorrhea, Nausea, Anemia, Society, Influenza-like illness, Therapy, ASH, Death, Marker, Back pain, University, AGIO, Medicine, Arthralgia

CAMBRIDGE, Mass., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease in an oral presentation (abstract #271) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being hosted Dec. 9-12, 2023, in San Diego.

Key Points: 
  • The safety profile for mitapivat observed in the study was generally consistent with previously reported data in other studies of sickle cell disease and other hemolytic anemias.
  • Improvements were observed in annualized rates of sickle cell pain crises, and markers of hemolysis and erythropoiesis for both mitapivat treatment arms compared to placebo.
  • “Currently there are no approved oral therapies that address both sickle cell pain crises and chronic anemia, two of the hallmark symptoms of the disease.
  • Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients With Sickle Cell Disease: RISE UP Phase 2 Results
    Oral Abstract Session: 114.

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

Retrieved on: 
星期一, 十月 23, 2023
MITRA, Abdominal pain, Headache, Health, Menopause, Diarrhea, Liver, California Healthcare Institute, CEST, Research, Nausea, Dysmenorrhea, Growth, Pregnancy, Irritability, Partnership, Menstruation, Weakness, ASEAN, Fuji, Depression, Somatic symptom disorder, Nikkei, Brussels Stock Exchange, Birth, Patient, Back pain, Fatigue, Pharmaceutical industry, Birth control, Estetrol

The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.

Key Points: 
  • The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.
  • Fuji Pharma obtained the right to commercialize both ESTELLE® and DONESTA® in Japan and the ASEAN region in 2016, targeting a potential market of 330 million patients.
  • David Horn Solomon, CEO at Mithra: “We are very proud of our partnership with Fuji Pharma and today’s announcement marks another key milestone in Mithra’s drive for growth and achieving its mission.
  • The global dysmenorrhea market was worth EUR 257 million in 20221.

South Africa's traditional medicines should be used in modern health care

Retrieved on: 
星期二, 八月 29, 2023
Inflammation, Infection, Asthma, Urinary tract infection, Cyclopia, Headache, Inhalation, Failure, Arthritis, Diabetes, Ear, Birth, Fever, COVID-19, Eye, Policy, Dysmenorrhea, Skin, World Health Organization, Skin and skin structure infection, Medicine, Research, Toxicity, System, Pain, Plant, Respiratory tract infection, Patient, Tuberculosis, Patient safety, Disease, Knowledge, Ulcer, Cough, WHO, Safety, Pharmaceutical industry, Health care, Medicinal plants, Dentistry, Frankincense, Birth control, Dietary supplement, African, Hoodia

The growing recognition of traditional medicine resulted in the first World Health Organization global summit on the topic, in August 2023, with the theme “Health and Wellbeing for All”.

Key Points: 
  • The growing recognition of traditional medicine resulted in the first World Health Organization global summit on the topic, in August 2023, with the theme “Health and Wellbeing for All”.
  • Traditional medicines are widely used in South Africa, with up to 60% of South Africans estimated to be reliant on traditional medicine as a primary source of healthcare .
  • Recognition of traditional medicine as an alternative or joint source of healthcare to that of standard, conventional medicine has proven challenging.

What are traditional medicines?

    • Traditional medicine encompasses a number of healthcare practices aimed at either preventing or treating acute or chronic complaints through the application of indigenous knowledge, beliefs and approaches.
    • Traditional medicine practices also have a place in ritualistic activities and communicating with ancestors.
    • The harvested plants are most often sold at traditional medicine muthi markets.

Uses of medicinal plants

    • Read more:
      We tested plants used for contraception in South Africa.
    • Here's what we found

      The most commonly traded medicinal plants in South Africa are listed below along with their traditional uses: Buchu – Urinary tract infections; skin infections; sexually transmitted infections; fever; respiratory tract infections; high blood pressure; gastrointestinal complaints.

    • Read more:
      Africa is a treasure trove of medicinal plants: here are seven that are popular

      There are many ways in which traditional medicine may be used.

    • Harvesting of the roots, however, poses concerns about the conservation of these medicinal plants.
    • The South African government, with the draft policy on African traditional medicine Notice 906 of 2008 outlines considerations aimed at ensuring the conservation of these plants through counteracting unsustainable harvesting practises.

Obstacles to traditional medicine use

    • The limited research investigating interactions posed should a patient be making use of both traditional and conventional medicine is a concern.
    • During the COVID-19 pandemic, many patients used traditional remedies for the prevention of infection or treatment.

Sharing information


    The WHO in its Traditional Medicine Strategy for 2014-2023 report emphasised the need for using traditional medicine to achieve increased healthcare. Key role players from both systems of healthcare need to be able to share information freely. The need for policy development is key. Both conventional and traditional medicine practitioners would need to be aware of and engage with patients on all the medicines they are taking.

Understanding the whole patient

    • A comprehensive understanding of a patient’s health profile makes care easier.
    • This could also prevent treatment failures, promote patient safety, prevent adverse interactions and minimise risks.